Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques

PLoS Neglected Tropical Diseases

Volumn 11, Issue 6, 2017, Pages

  Broeckel, Rebecca ^a   Fox, Julie M ^b   Haese, Nicole ^a   Kreklywich, Craig N ^a   Sukulpovi Petty, Soila ^b   Legasse, Alfred ^c   Smith, Patricia P ^a   Denton, Michael ^a   Corvey, Carsten ^d   Krishnan, Shiv ^d   Colgin, Lois M A ^c   Ducore, Rebecca M ^c   Lewis, Anne D ^c   Axthelm, Michael K ^a,c   Mandron, Marie ^e   Cortez, Pierre ^e   Rothblatt, Jonathan ^d   Rao, Ercole ^e   Focken, Ingo ^e   Carter, Kara ^d   Sapparapau, Gopal ^f   Crowe, James E ^f   Diamond, Michael S ^b   Streblow, Daniel N ^a,c   more..

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d SANOFI   (United States)

^e SANOFI   (France)

^f VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; HUMAN MONOCLONAL ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; RANTES; SVIR001; SVIR002; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; VIRUS ANTIBODY;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; CHIKUNGUNYA; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL FILTRATION CHROMATOGRAPHY; HISTOLOGY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHESUS MONKEY; VIREMIA; VIRUS ISOLATION; VIRUS LOAD; VIRUS NEUTRALIZATION; ANIMAL; B LYMPHOCYTE; CHIKUNGUNYA FEVER; CHIKUNGUNYA VIRUS; DISEASE MODEL; IMMUNOLOGY; PATHOLOGY; PRECLINICAL STUDY; T LYMPHOCYTE; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; B-LYMPHOCYTES; CHIKUNGUNYA FEVER; CHIKUNGUNYA VIRUS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; IMMUNOLOGIC FACTORS; MACACA MULATTA; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 85021661518     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0005637     Document Type: Article

References (55)

1. Voss JE, Vaney MC, Duquerroy S, Vonrhein C, Girard-Blanc C, Crublet E, et al. Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography. Nature. 2010;468(7324):709–12. doi: 10.1038/nature09555 21124458.
2. Schilte C, Staikowsky F, Staikovsky F, Couderc T, Madec Y, Carpentier F, et al. Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal study. PLoS Negl Trop Dis. 2013;7(3):e2137. doi: 10.1371/journal.pntd.0002137 23556021; PubMed Central PMCID: PMCPMC3605278.
3. Hoarau JJ, Jaffar Bandjee MC, Krejbich Trotot P, Das T, Li-Pat-Yuen G, Dassa B, et al. Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response. J Immunol. 2010;184(10):5914–27. doi: 10.4049/jimmunol.0900255 20404278
4. Sissoko D, Malvy D, Ezzedine K, Renault P, Moscetti F, Ledrans M, et al. Post-epidemic Chikungunya disease on Reunion Island: course of rheumatic manifestations and associated factors over a 15-month period. PLoS Negl Trop Dis. 2009;3(3):e389. doi: 10.1371/journal.pntd.0000389 19274071; PubMed Central PMCID: PMCPMC2647734.
5. Gerardin P, Guernier V, Perrau J, Fianu A, Le Roux K, Grivard P, et al. Estimating Chikungunya prevalence in La Reunion Island outbreak by serosurveys: two methods for two critical times of the epidemic. BMC Infect Dis. 2008;8:99. doi: 10.1186/1471-2334-8-99 18662384; PubMed Central PMCID: PMC2528011.
6. Sergon K, Yahaya AA, Brown J, Bedja SA, Mlindasse M, Agata N, et al. Seroprevalence of Chikungunya virus infection on Grande Comore Island, union of the Comoros, 2005. Am J Trop Med Hyg. 2007;76(6):1189–93. 17556634.
7. Sergon K, Njuguna C, Kalani R, Ofula V, Onyango C, Konongoi LS, et al. Seroprevalence of Chikungunya virus (CHIKV) infection on Lamu Island, Kenya, October 2004. Am J Trop Med Hyg. 2008;78(2):333–7. 18256441.
8. Chikungunya Fever Situation in the Country during 2006 (Prov.): National Vector Borne Disease Control Programme, Delhi, 2006. Available from: http://www.nvbdcp.gov.in/Chikun-cases.html.
9. Chen R, Puri V, Fedorova N, Lin D, Hari KL, Jain R, et al. Comprehensive Genome Scale Phylogenetic Study Provides New Insights on the Global Expansion of Chikungunya Virus. J Virol. 2016;90(23):10600–11. Epub 2016/11/14. doi: 10.1128/JVI.01166-16 27654297; PubMed Central PMCID: PMCPMC5110187.
10. Leparc-Goffart I, Nougairede A, Cassadou S, Prat C, de Lamballerie X, Chikungunya in the Americas. Lancet. 2014;383(9916):514. doi: 10.1016/S0140-6736(14)60185-9 24506907.
11. Chikungunya: Statistics Data: Pan American Health Organization; [cited 2016 November]. Available from: http://www.paho.org/hq/index.php?option=com_topics&view=readall&cid=5927&Itemid=40931&lang=en.
12. Robinson MC, An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952–53. I. Clinical features. Trans R Soc Trop Med Hyg. 1955;49(1):28–32. 14373834.
13. Borgherini G, Poubeau P, Staikowsky F, Lory M, Le Moullec N, Becquart JP, et al. Outbreak of chikungunya on Reunion Island: early clinical and laboratory features in 157 adult patients. Clin Infect Dis. 2007;44(11):1401–7. 17479933. doi: 10.1086/517537
14. Laurent P, Le Roux K, Grivard P, Bertil G, Naze F, Picard M, et al. Development of a sensitive real-time reverse transcriptase PCR assay with an internal control to detect and quantify chikungunya virus. Clin Chem. 2007;53(8):1408–14. doi: 10.1373/clinchem.2007.086595 17586592
15. Economopoulou A, Dominguez M, Helynck B, Sissoko D, Wichmann O, Quenel P, et al. Atypical Chikungunya virus infections: clinical manifestations, mortality and risk factors for severe disease during the 2005–2006 outbreak on Reunion. Epidemiol Infect. 2009;137(4):534–41. doi: 10.1017/S0950268808001167 18694529
16. Rajapakse S, Rodrigo C, Rajapakse A, Atypical manifestations of chikungunya infection. Trans R Soc Trop Med Hyg. 2010;104(2):89–96. doi: 10.1016/j.trstmh.2009.07.031 19716149.
17. Borgherini G, Poubeau P, Jossaume A, Gouix A, Cotte L, Michault A, et al. Persistent arthralgia associated with chikungunya virus: a study of 88 adult patients on reunion island. Clin Infect Dis. 2008;47(4):469–75. 18611153. doi: 10.1086/590003
18. Gérardin P, Fianu A, Malvy D, Mussard C, Boussaïd K, Rollot O, et al. Perceived morbidity and community burden after a Chikungunya outbreak: the TELECHIK survey, a population-based cohort study. BMC Med. 2011;9:5. doi: 10.1186/1741-7015-9-5 21235760; PubMed Central PMCID: PMCPMC3029216.
19. Ozden S, Huerre M, Riviere JP, Coffey LL, Afonso PV, Mouly V, et al. Human muscle satellite cells as targets of Chikungunya virus infection. PLoS ONE. 2007;2(6):e527. 17565380. doi: 10.1371/journal.pone.0000527
20. Akahata W, Yang ZY, Andersen H, Sun S, Holdaway HA, Kong WP, et al. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med. 2010;16(3):334–8. 20111039. doi: 10.1038/nm.2105
21. Plante K, Wang E, Partidos CD, Weger J, Gorchakov R, Tsetsarkin K, et al. Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism. PLoS Pathog. 2011;7(7):e1002142. doi: 10.1371/journal.ppat.1002142 21829348; PubMed Central PMCID: PMCPMC3145802.
22. Chu H, Das SC, Fuchs JF, Suresh M, Weaver SC, Stinchcomb DT, et al. Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model. Vaccine. 2013;31(33):3353–60. doi: 10.1016/j.vaccine.2013.05.059 23727003; PubMed Central PMCID: PMCPMC3731778.
23. Yoon IK, Alera MT, Lago CB, Tac-An IA, Villa D, Fernandez S, et al. High rate of subclinical chikungunya virus infection and association of neutralizing antibody with protection in a prospective cohort in the Philippines. PLoS Negl Trop Dis. 2015;9(5):e0003764. doi: 10.1371/journal.pntd.0003764 25951202; PubMed Central PMCID: PMCPMC4423927.
24. Galatas B, Ly S, Duong V, Baisley K, Nguon K, Chan S, et al. Long-Lasting Immune Protection and Other Epidemiological Findings after Chikungunya Emergence in a Cambodian Rural Community, April 2012. PLoS Negl Trop Dis. 2016;10(1):e0004281. doi: 10.1371/journal.pntd.0004281 26752630; PubMed Central PMCID: PMCPMC4713465.
25. Kam YW, Simarmata D, Chow A, Her Z, Teng TS, Ong EK, et al. Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection. J Infect Dis. 2012;205(7):1147–54. 22389226. doi: 10.1093/infdis/jis033
26. Kam YW, Lum FM, Teo TH, Lee WW, Simarmata D, Harjanto S, et al. Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein. EMBO Mol Med. 2012;4(4):330–43. 22389221. doi: 10.1002/emmm.201200213
27. Kam YW, Lee WW, Simarmata D, Harjanto S, Teng TS, Tolou H, et al. Longitudinal analysis of the human antibody response to Chikungunya virus infection: implications for serodiagnosis and vaccine development. J Virol. 2012;86(23):13005–15. doi: 10.1128/JVI.01780-12 23015702
28. Smith SA, Silva LA, Fox JM, Flyak AI, Kose N, Sapparapu G, et al. Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus. Cell Host Microbe. 2015;18(1):86–95. doi: 10.1016/j.chom.2015.06.009 26159721; PubMed Central PMCID: PMCPMC4501771.
29. Kam YW, Pok KY, Eng KE, Tan LK, Kaur S, Lee WW, et al. Sero-prevalence and cross-reactivity of chikungunya virus specific anti-E2EP3 antibodies in arbovirus-infected patients. PLoS Negl Trop Dis. 2015;9(1).
30. Kam YW, Lee WW, Simarmata D, Le Grand R, Tolou H, Merits A, et al. Unique epitopes recognized by antibodies induced in Chikungunya virus-infected non-human primates: implications for the study of immunopathology and vaccine development. PLoS One. 2014;9(4):e95647. doi: 10.1371/journal.pone.0095647 24755730; PubMed Central PMCID: PMCPMC3995782.
31. Couderc T, Khandoudi N, Grandadam M, Visse C, Gangneux N, Bagot S, et al. Prophylaxis and therapy for Chikungunya virus infection. J Infect Dis. 2009;200(4):516–23. 19572805. doi: 10.1086/600381
32. Pal P, Dowd KA, Brien JD, Edeling MA, Gorlatov S, Johnson S, et al. Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus. PLoS Pathog. 2013;9(4):e1003312. doi: 10.1371/journal.ppat.1003312 23637602; PubMed Central PMCID: PMCPMC3630103.
33. Partidos CD, Weger J, Brewoo J, Seymour R, Borland EM, Ledermann JP, et al. Probing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signaling. Vaccine. 2011;29(16):3067–73. doi: 10.1016/j.vaccine.2011.01.076 21300099; PubMed Central PMCID: PMCPMC3081687.
34. Selvarajah S, Sexton NR, Kahle KM, Fong RH, Mattia KA, Gardner J, et al. A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease. PLoS Negl Trop Dis. 2013;7(9):e2423. doi: 10.1371/journal.pntd.0002423 24069479; PubMed Central PMCID: PMCPMC3772074.
35. Hawman DW, Stoermer KA, Montgomery SA, Pal P, Oko L, Diamond MS, et al. Chronic joint disease caused by persistent Chikungunya virus infection is controlled by the adaptive immune response. J Virol. 2013;87(24):13878–88. doi: 10.1128/JVI.02666-13 24131709; PubMed Central PMCID: PMC3838294.
36. Lum FM, Teo TH, Lee WW, Kam YW, Rénia L, Ng LF, An essential role of antibodies in the control of Chikungunya virus infection. J Immunol. 2013;190(12):6295–302. doi: 10.4049/jimmunol.1300304 23670192; PubMed Central PMCID: PMCPMC3677171.
37. Poo YS, Rudd PA, Gardner J, Wilson JA, Larcher T, Colle MA, et al. Multiple immune factors are involved in controlling acute and chronic chikungunya virus infection. PLoS Negl Trop Dis. 2014;8(12):e3354. doi: 10.1371/journal.pntd.0003354 25474568; PubMed Central PMCID: PMCPMC4256279.
38. Pal P, Fox JM, Hawman DW, Huang YJ, Messaoudi I, Kreklywich C, et al. Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes. J Virol. 2014;88(15):8213–26. doi: 10.1128/JVI.01032-14 24829346; PubMed Central PMCID: PMC4135940.
39. Messaoudi I, Vomaske J, Totonchy T, Kreklywich CN, Haberthur K, Springgay L, et al. Chikungunya virus infection results in higher and persistent viral replication in aged rhesus macaques due to defects in anti-viral immunity. PLoS Negl Trop Dis. 2013;7(7):e2343. doi: 10.1371/journal.pntd.0002343 23936572; PubMed Central PMCID: PMC3723534.
40. Bellini R, Medici A, Calzolari M, Bonilauri P, Cavrini F, Sambri V, et al. Impact of Chikungunya virus on Aedes albopictus females and possibility of vertical transmission using the actors of the 2007 outbreak in Italy. PLoS One. 2012;7(2):e28360. doi: 10.1371/journal.pone.0028360 22383945; PubMed Central PMCID: PMCPMC3287980.
41. Larghi OP, Nebel AE, Rabies virus inactivation by binary ethylenimine: new method for inactivated vaccine production. J Clin Microbiol. 1980;11(2):120–2. 7358836; PubMed Central PMCID: PMCPMC273335.
42. Habib M, Hussain I, Irshad H, Yang ZZ, Shuai JB, Chen N, Immunogenicity of formaldehyde and binary ethylenimine inactivated infectious bursal disease virus in broiler chicks. J Zhejiang Univ Sci B. 2006;7(8):660–4. doi: 10.1631/jzus.2006.B0660 16845721; PubMed Central PMCID: PMCPMC1533761.
43. Bahnemann HG, Binary ethylenimine as an inactivant for foot-and-mouth disease virus and its application for vaccine production. Arch Virol. 1975;47(1):47–56. 167679.
44. Chen CI, Clark DC, Pesavento P, Lerche NW, Luciw PA, Reisen WK, et al. Comparative pathogenesis of epidemic and enzootic Chikungunya viruses in a pregnant Rhesus macaque model. Am J Trop Med Hyg. 2010;83(6):1249–58. doi: 10.4269/ajtmh.2010.10-0290 21118930; PubMed Central PMCID: PMC2990040.
45. Labadie K, Larcher T, Joubert C, Mannioui A, Delache B, Brochard P, et al. Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages. J Clin Invest. 2010;120(3):894–906. 20179353. doi: 10.1172/JCI40104
46. Binn LN, Harrison VR, Randall R, Patterns of viremia and antibody observed in rhesus monkeys inoculated with chikungunya and other serologically related group A arboviruses. Am J Trop Med Hyg. 1967;16(6):782–5. 4965218.
47. Simon F, Parola P, Grandadam M, Fourcade S, Oliver M, Brouqui P, et al. Chikungunya infection: an emerging rheumatism among travelers returned from Indian Ocean islands. Report of 47 cases. Medicine. 2007;86(3):123–37. doi: 10.1097/MD/0b013e31806010a5 17505252
48. Manimunda SP, Vijayachari P, Uppoor R, Sugunan AP, Singh SS, Rai SK, et al. Clinical progression of chikungunya fever during acute and chronic arthritic stages and the changes in joint morphology as revealed by imaging. Trans R Soc Trop Med Hyg. 2010;104(6):392–9. doi: 10.1016/j.trstmh.2010.01.011 20171708.
49. Chow A, Her Z, Ong EK, Chen JM, Dimatatac F, Kwek DJ, et al. Persistent arthralgia induced by Chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor. J Infect Dis. 2011;203(2):149–57. doi: 10.1093/infdis/jiq042 21288813; PubMed Central PMCID: PMCPMC3071069.
50. Wauquier N, Becquart P, Nkoghe D, Padilla C, Ndjoyi-Mbiguino A, Leroy EM, The acute phase of Chikungunya virus infection in humans is associated with strong innate immunity and T CD8 cell activation. J Infect Dis. 2011;204(1):115–23. 21628665. doi: 10.1093/infdis/jiq006
51. Venugopalan A, Ghorpade RP, Chopra A, Cytokines in acute chikungunya. PLoS One. 2014;9(10):e111305. doi: 10.1371/journal.pone.0111305 25343623; PubMed Central PMCID: PMCPMC4208842.
52. Kelvin AA, Banner D, Silvi G, Moro ML, Spataro N, Gaibani P, et al. Inflammatory cytokine expression is associated with chikungunya virus resolution and symptom severity. PLoS Negl Trop Dis. 2011;5(8):e1279. doi: 10.1371/journal.pntd.0001279 21858242; PubMed Central PMCID: PMCPMC3156690.
53. Ng LF, Chow A, Sun YJ, Kwek DJ, Lim PL, Dimatatac F, et al. IL-1beta, IL-6, and RANTES as biomarkers of Chikungunya severity. PLoS One. 2009;4(1):21.
54. Appassakij H, Khuntikij P, Kemapunmanus M, Wutthanarungsan R, Silpapojakul K, Viremic profiles in asymptomatic and symptomatic chikungunya fever: a blood transfusion threat?Transfusion. 2013;53(10 Pt 2):2567–74. doi: 10.1111/j.1537-2995.2012.03960.x 23176378.
55. Panning M, Grywna K, van Esbroeck M, Emmerich P, Drosten C, Chikungunya fever in travelers returning to Europe from the Indian Ocean region, 2006. Emerg Infect Dis. 2008;14(3):416–22. doi: 10.3201/eid1403.070906 18325256